182 related articles for article (PubMed ID: 24700302)
1. Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.
Jiang BS; Beasley GM; Speicher PJ; Mosca PJ; Morse MA; Hanks B; Salama A; Tyler DS
Ann Surg Oncol; 2014 Aug; 21(8):2525-31. PubMed ID: 24700302
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.
Joseph RW; Eckel-Passow JE; Sharma R; Liu P; Parker A; Jakob J; Buchbinder E; Bassett RL; Davies MA; Hwu P; Atkins MB; Sullivan RJ
J Immunother; 2012; 35(9):711-5. PubMed ID: 23090080
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.
Weide B; Martens A; Wistuba-Hamprecht K; Zelba H; Maier L; Lipp HP; Klumpp BD; Soffel D; Eigentler TK; Garbe C
Cancer Immunol Immunother; 2017 Apr; 66(4):441-449. PubMed ID: 28008452
[TBL] [Abstract][Full Text] [Related]
4. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
5. Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma.
Wong J; Chen YA; Fisher KJ; Beasley GM; Tyler DS; Zager JS
Ann Surg Oncol; 2014 Feb; 21(2):650-5. PubMed ID: 24162840
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Prieto PA; Yang JC; Sherry RM; Hughes MS; Kammula US; White DE; Levy CL; Rosenberg SA; Phan GQ
Clin Cancer Res; 2012 Apr; 18(7):2039-47. PubMed ID: 22271879
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Moya-Plana A; Herrera Gómez RG; Rossoni C; Dercle L; Ammari S; Girault I; Roy S; Scoazec JY; Vagner S; Janot F; Eggermont AMM; Robert C
Cancer Immunol Immunother; 2019 Jul; 68(7):1171-1178. PubMed ID: 31172258
[TBL] [Abstract][Full Text] [Related]
8. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
[TBL] [Abstract][Full Text] [Related]
10. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
11. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
12. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma.
Gyorki DE; Yuan J; Mu Z; Zaidi B; Pulitzer M; Busam K; Brady MS; Coit DG; Allison JP; Wolchok JD; Ariyan CE
Ann Surg Oncol; 2013 Sep; 20(9):3106-11. PubMed ID: 23681603
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
14. A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
Postow MA; Knox SJ; Goldman DA; Elhanati Y; Mavinkurve V; Wong P; Halpenny D; Reddy SK; Vado K; McCabe D; Ramirez KA; Macri M; Schwarzenberger P; Ricciardi T; Ryan A; Venhaus R; Momtaz P; Shoushtari AN; Callahan MK; Chapman PB; Wolchok JD; Subrahmanyam PB; Maecker HT; Panageas KS; Barker CA
Clin Cancer Res; 2020 Jul; 26(13):3193-3201. PubMed ID: 32205463
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Postow MA; Chesney J; Pavlick AC; Robert C; Grossmann K; McDermott D; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor D; Salama AK; Taylor M; Ott PA; Rollin LM; Horak C; Gagnier P; Wolchok JD; Hodi FS
N Engl J Med; 2015 May; 372(21):2006-17. PubMed ID: 25891304
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Kropp LM; De Los Santos JF; McKee SB; Conry RM
J Immunother; 2016; 39(9):373-378. PubMed ID: 27662339
[TBL] [Abstract][Full Text] [Related]
17. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
[TBL] [Abstract][Full Text] [Related]
18. Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.
Ariyan CE; Brady MS; Siegelbaum RH; Hu J; Bello DM; Rand J; Fisher C; Lefkowitz RA; Panageas KS; Pulitzer M; Vignali M; Emerson R; Tipton C; Robins H; Merghoub T; Yuan J; Jungbluth A; Blando J; Sharma P; Rudensky AY; Wolchok JD; Allison JP
Cancer Immunol Res; 2018 Feb; 6(2):189-200. PubMed ID: 29339377
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
Weber J; Gibney G; Kudchadkar R; Yu B; Cheng P; Martinez AJ; Kroeger J; Richards A; McCormick L; Moberg V; Cronin H; Zhao X; Schell M; Chen YA
Cancer Immunol Res; 2016 Apr; 4(4):345-53. PubMed ID: 26873574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]